Free Trial
NASDAQ:ALVR

AlloVir Q4 2023 Earnings Report

AlloVir logo
$5.41 -0.42 (-7.20%)
As of 05/5/2025

AlloVir EPS Results

Actual EPS
-$12.19
Consensus EPS
-$9.89
Beat/Miss
Missed by -$2.30
One Year Ago EPS
N/A

AlloVir Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AlloVir Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 15, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

AlloVir's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

AlloVir Earnings Headlines

Kalaris Announces Closing of Merger with AlloVir
Trump's Neighbor Issues Urgent Financial Warning: "The Economic Singularity Is Coming"
They call me "The Seer of Wall Street" for a reason. When I warned about Enron in 2001, most analysts were still rating it a "buy." When I developed my system, the financial establishment scoffed — until my system began outperforming nearly every fund manager on the Street.
Kalaris, AlloVir announce stockholder approval of merger
See More AlloVir Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email.

About AlloVir

AlloVir (NASDAQ:ALVR) engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

View AlloVir Profile

More Earnings Resources from MarketBeat